ArticleJournal of experimental & clinical cancer research : CR2019
Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.
Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 67 citations in OpenAlex.
- Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma.Cell reports. Medicine · 2025Trial
- Immune killer cells treatment for previously treated stage IV NSCLC patients.Scientific reports · 2024Trial
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Nature communications · 2024Trial
- Integrated Single Cell Analysis Reveals the Transcriptional Heterogeneity of Mouse Double Negative T Cells.International journal of molecular sciences · 2026Article
- FcεRIγ reinforces double-negative T cell-mediated antibody-dependent cellular cytotoxicity against tumor cells.Journal of molecular cell biology · 2026Article
- Article
- FAPαAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Development and validation of a diagnostic machine learning model for gastric cancer risk based on double-negative T cell-related features.Cancer cell international · 2026Article
- A pan-cancer single cell landscape reveals heterogeneity and functional diversity of double-negative T cells.Molecular cancer · 2026Article
- Immune dysregulation in endometriosis: the T cell perspective.Frontiers in immunology · 2026Review
- Proliferative double-negative T (DNT)-cell responses to PD-1 blockade therapy were positively correlated with good clinical outcomes in non-small cell lung cancer patients.Pakistan journal of medical sciences · 2026Article
- Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma.Oncoimmunology · 2025Article
- SLAMF7 promotes TCRαβJournal of experimental & clinical cancer research : CR · 2025Article
- Causal association of breast cancer with immune cells: new evidence from bi-directional Mendelian randomization using GWAS summary statistics.BMC cancer · 2025Article
- Assessing the causal association between 731 immunophenotypes and the risk of colorectal cancer: a Mendelian randomization study.BMC cancer · 2025Article
- Article
- High CD38 expression defines a mitochondrial function-adapted CD8Cancer immunology, immunotherapy : CII · 2025Article
- Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective.Frontiers in immunology · 2025Review
- Differential effects of immobilized CCL21 and ICAM1 on TILs with distinct expansion properties.Frontiers in immunology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundThough immune checkpoint blockade (ICB) against PD-1 has shown success in the treatment of lung cancer, not all patients respond. We have previously shown that adoptive transfer of double negative T (DNT) cells expanded from healthy donors can target leukemia but their role in treating established lung cancer is not clear. Here we explore the role of human DNT cells in targeting late-stage established lung cancer either alone or in combination with Nivolumab (anti-PD-1 antibody) and describe underlying mechanisms.
methodsDNT cells from resected lung cancer tissue of patients were analyzed by flow cytometry to determine their infiltration and PD-1 expression. Expansion capacity and anti-tumor function of lung cancer patient and healthy donor DNT cells were compared. Late-stage lung cancer xenograft models were developed to determine the anti-tumor effect of DNT cells alone or in combination with anti-PD-1 antibody, and the level of tumor-infiltrating DNT cells was quantified by histology and characterized by flow cytometry.
resultsPatient-derived tumor infiltrating lymphocytes contained a lower frequency of DNT cells with a higher expression of PD-1 relative to normal lung tissue. Ex vivo expanded patient- and healthy donor-derived DNT cells showed similar levels of cytotoxicity against lung cancer cells in vitro. Healthy donor-derived DNT cells significantly inhibited the growth of late-stage lung cancer xenografts, which was further augmented by anti-PD-1 through increased DNT cell tumor infiltration.
conclusionThis study supports the use of DNT cells for adoptive cellular therapy against lung cancer either alone or in combination with anti-PD-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.